Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 20/20 | 1.00 |
| ▸ | ADAM10 | O14672 | 2/20 | 1.00 |
| ▸ | MMP3 | P08254 | 2/20 | 1.00 |
| ▸ | ADAM9 | Q13443 | 1/20 | 1.00 |
| ▸ | MMP1 | P03956 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1504678 | 1.00 | ADAM17 (1.00) | ADAM17ADAM10MMP3ADAM9MMP1 | |
| SCHEMBL1504826 | 1.00 | ADAM17 (1.00) | ADAM17ADAM10MMP3ADAM9MMP1 | |
| SCHEMBL1504793 | 0.92 | ADAM17 (1.00) | ADAM17ADAM10MMP3ADAM9MMP1 | |
| SCHEMBL1504584 | 0.91 | ADAM17 (0.83) | ADAM17ADAM10MMP3ADAM9MMP1 | |
| SCHEMBL10275858 | 0.91 | ADAM17 (0.83) | ADAM17ADAM10MMP3ADAM9MMP1 | |
| SCHEMBL10276287 | 0.91 | ADAM17 (0.83) | ADAM17ADAM10MMP3ADAM9MMP1 | |
| SCHEMBL1504527 | 0.90 | ADAM17 (0.81) | ADAM17ADAM10MMP3ADAM9MMP1 | |
| SCHEMBL1504780 | 0.90 | ADAM17 (0.81) | ADAM17ADAM10MMP3ADAM9MMP1 | |
| SCHEMBL1504688 | 0.89 | ADAM17 (0.81) | ADAM17ADAM10MMP3ADAM9MMP1 | |
| SCHEMBL1504760 | 0.88 | ADAM17 (1.00) | ADAM17ADAM10MMP3ADAM9MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9115102-B2 | N-[2-hydroxycarbamoyl-2-(piperazinyl) ethyl] benzamide compounds, their preparation and their use as TACE inhibitors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2015-08-25 | — | — | US | claimed |
| EP-2477968-B1 | N-[2-HYDROXYCARBAMOYL-2-(PIPERAZINYL)ETHYL]BENZAMIDE COMPOUNDS, THEIR PREPARATION AND THEIR USE AS TACE INHIBITORS | GALDERMA RES & DEV (FR) | 2013-10-23 | — | — | EP | claimed |
| EP-2477968-A1 | N- [2-HYDROXYCARBAMOYL-2- (PIPERAZINYL) ETHYL]BENZAMIDE COMPOUNDS, THEIR PREPARATION AND THEIR USE AS TACE INHIBITORS | Galderma Research & Development (FR) | 2012-07-25 | — | — | EP | claimed |
| US-20120178934-A1 | N- [2-HYDROXYCARBAMOYL-2- (PIPERAZINYL) ETHYL] BENZAMIDE COMPOUNDS, THEIR PREPARATION AND THEIR USE AS TACE INHIBITORS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2012-07-12 | — | — | US | claimed |
| WO-2011033009-A1 | N- [2-HYDROXYCARBAMOYL-2- (PIPERAZINYL) ETHYL] BENZAMIDE COMPOUNDS, THEIR PREPARATION AND THEIR USE AS TACE INHIBITORS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-03-24 | — | — | WO | claimed |
| US-9115102-B2 | N-[2-hydroxycarbamoyl-2-(piperazinyl) ethyl] benzamide compounds, their preparation and their use as TACE inhibitors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2015-08-25 | — | — | US | disclosed |
| EP-2477968-B1 | N-[2-HYDROXYCARBAMOYL-2-(PIPERAZINYL)ETHYL]BENZAMIDE COMPOUNDS, THEIR PREPARATION AND THEIR USE AS TACE INHIBITORS | GALDERMA RES & DEV (FR) | 2013-10-23 | — | — | EP | disclosed |
| EP-2477968-A1 | N- [2-HYDROXYCARBAMOYL-2- (PIPERAZINYL) ETHYL]BENZAMIDE COMPOUNDS, THEIR PREPARATION AND THEIR USE AS TACE INHIBITORS | Galderma Research & Development (FR) | 2012-07-25 | — | — | EP | disclosed |
| US-20120178934-A1 | N- [2-HYDROXYCARBAMOYL-2- (PIPERAZINYL) ETHYL] BENZAMIDE COMPOUNDS, THEIR PREPARATION AND THEIR USE AS TACE INHIBITORS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2012-07-12 | — | — | US | disclosed |
| WO-2011033009-A1 | N- [2-HYDROXYCARBAMOYL-2- (PIPERAZINYL) ETHYL] BENZAMIDE COMPOUNDS, THEIR PREPARATION AND THEIR USE AS TACE INHIBITORS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178934-A1 | N- [2-HYDROXYCARBAMOYL-2- (PIPERAZINYL) ETHYL] BENZAMIDE COMPOUNDS, THEIR PREPARATION AND THEIR USE AS TACE INHIBITORS | CTSB, TPSAB1, PIGS | ADAM17 6/4885ADAM10 20/4885MMP3 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.